Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — FY2021 Earnings Presentation
17 slides from Laboratorio Reig Jofre's earnings presentation, 2022
Slide 1: Results Fourth Quarter of 2021
RESULTS Fourth Quarter of 2021 PAGE 1
Slide 2: Disclaimer
DISCLAIMER This presentation does not contain any confidential material and may Reig Jofre is under no obligation to publicly disclose the results of revising these include publicly available market information that has not been forward-looking statements to reflect the occurrence of unanticipated e
Slide 3: Table of Contents
TABLE OF CONTENTS 01 2021 RESULTS 02 INCOME STATEMENT AND BALANCE SHEET 03 OUTLOOK FOR 2022 04 RJF SHARE PERFORMANCE RJF SHARE PERFORMANCE PAGE
Slide 4: Results 2021
Q4 2021 RESULTS 2021 01 PAGE
Slide 5: 2021 Results: revenues and EBITDA grew by 3%
2021 RESULTS REIG JOFRE's revenues and EBITDA grew by 3% in 2021 SALES +3% The cumulative sales figure in 2021 reached €236 million, exceeding the 2020 year-end by 3%. Recovery from the sale of prescription medical products from the Speciality Pharmacare division, €236.2 million and the good perfo
Slide 6: Revenues by Business Unit
INGRESOS POR BUSINESS UNIT PHARMACEUTICAL SPECIALTY CONSUMER TECHNOLOGIES PHARMACARE HEALTHCARE Antibiotics Osteoarticular OTC Injectables / Lyophilisates Dermatology Energy Stress and sleep € 104.2 million € 75.5 million Weight control Beauty € 56.5 million 44 % -7% 32 % +14% 23 % +8% The Pharmac
Slide 7: Sales by Geographical Area
SALES BY GEOGRAPHICAL AREA Rest of Rest of SPAIN EUROPE WORLD 45% 43% 12% European €105.5 million €101 . 4 million €29 . 3 million Union 37% Rest of Europe 6% + 1% + 4% + 3% Asia 7% Africa 3% The Spanish market, as a whole, has resisted the sharp drop in the consumption of Spain America antibiotic
Slide 8: Income Statement and Balance Sheet
Q4 2021 INCOME STATEMENT BALANCE SHEET 02 PAGE
Slide 9: Income Statement
INCOME STATEMENT 2021/2020 Outlook Q4 2021 thousand euros 31/12/2021 31/12/2020 A 3% increase in sales figures, with a 61% gross sales margin, in line with previous year. Turnover 236.231 230.079 Procurements -86.659 -92.128 The R&D capitalisation rate (work performed for fixed assets) is upheld
Slide 10: Balance Sheet: Assets and 2021 Investment
BALANCE SHEET 16,7 Q4 2021 thousand euros 31/12/2021 31/12/2020 2021 INVESTMENT € million ASSETS Goodwill 29.843 29.972 Other intangible assets 77.727 82.832 Property, plant and equipment 92.387 85.284 Investments in equity-accounted investees 1.948 1.308 Non-current financial assets measured at fai
Slide 11: Balance Sheet: Equity, Liabilities and Net Financial Debt
BALANCE SHEET Q4 2021 thousand euros 31/12/2021 31/12/2020 NET FINANCIAL DEBT Debt|EBITDA EQUITY AND LIABILITIES 69.0 2021 2021 TOTAL EQUITY 188.514 184.478 year- € million year- 2.5 end end Capital grants 3.065 2.438 2020 55.1 2020 Provisions Financial liabilities with credit institutions 201 34.67
Slide 12: Outlook 2022
Q4 2021 OUTLOOK 2022 03 PAGE 12
Slide 13: Outlook for 2022
OUTLOOK FOR 2022 REIG JOFRE, in its commitment to society and the pandemic situation, has made a significant effort in 2021to make the new injectables plant in Barcelona available and adapted to the manufacturing requirements of COVID-19 vaccines in case of future need. The year 2021 ends with a con
Slide 14: RJF Share Performance
Q4 2021 RJF SHARE PERFORMANCE 04 PAGE
Slide 15: RJF Share Performance 2021
RJF SHARE PERFORMANCE 2021 MARKET CAP €252MILLION Data as of December 31, 2021 SCRIP DIVIDEND 2021 6,50 Closing 6,25 • Remuneration € 0,039/share cash o acciones 6,00 31/12/21 • 98% shareholders opt for shares 5,75 5,50 3.26€ • Issuance of 629,805 shares (1% capital) 5,25 5,00 AVERAGE DAILY VOLUME 4
Slide 16: Further Information
FURTHER INFORMATION LATEST NEWS https://reigjofre.com/en/news/ SUSCRIPTION CENTER https://reigjofre.com/en/news/subscription-center/ PAGE
Slide 17: Thank you
Thank you Av. de les Flors 08970 Sant Joan Despi Barcelona, Spain Investor Relations T. +34 93 480 67 10 investors@reigjofre.com www.reigjofre.com PAGE